Rheumatic heart disease (RHD) remains the leading cause of acquired valvular heart disease in low- and middle-income countries, affecting an estimated 40 million individuals and disproportionately affecting children and young …
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk
Progesterone resistance in endometriosis reduces the efficacy of progestin. The non-classical progesterone receptor, progesterone receptor membrane component 1 (PGRMC1) may regulate progesterone signaling in the normal endometrium, but its expression …
Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet sex-specific risk factors are usually not included in conventional predictive models. Specifically, heart failure (HF) in women may …
Women remain underrepresented in clinical drug development despite their unique biological characteristics and growing disease burden. In China, this disparity is particularly concerning given the rising incidence of gynecologic conditions …
Patient-derived organoids (PDOs) have emerged as physiologically relevant three-dimensional (3D) culture systems that closely mimic the molecular and histological features of the human endometrium and associated malignancies. Owing to their …
Cancer treatments can deplete the ovarian follicle reserve, causing infertility and early menopause, with subsequent decline in cardiovascular, cognitive, and overall women's health. Medical measures to prevent this chemotherapy-induced ovarian …
Endometriosis (EMs) is a chronic, estrogen-dependent gynecological disorder characterized by the ectopic growth of endometrial tissue outside the uterus. Zinc Finger Protein 143 (ZNF143) is a DNA-binding transcription factor, yet …
PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer Medscape Reference
Calcitonin gene-related peptide (CGRP), a neuropeptide, has been implicated in autoimmune diseases, endometriosis, tumors, and primary headaches, including migraine. The development of a novel, fast-acting CGRP receptor antagonist administered via …